Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

NCT01606878 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT01606878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01606878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
April 29, 2013
Completion date
December 31, 2018
Enrollment
46 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

childhood solid neoplasm, recurrent childhood anaplastic large cell lymphoma, recurrent neuroblastoma